Advertisement
Advertisement
TAK
Takeda Pharmaceutical Company Limited - ADR
18.35
USDSponsored
+0.11
+0.60%
Aug 25, 15:59 UTC -4
Closed
After-Market
18.27
-0.08
-0.42%
TAK Earnings Reports
Positive Surprise Ratio
TAK beat 29 of 41 last estimates.
71%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q2 27 (Revenue/ EPS)
$1.16T
/$47.57
Implied change from Q1 27 (Revenue/ EPS)
-5.07%
/-32.56%
Implied change from Q2 26 (Revenue/ EPS)
+4.07%
/-735.96%
Takeda Pharmaceutical Company Limited - ADR earnings per share and revenue
On Jul 30, 2026, TAK reported earnings of 70.54 USD per share (EPS) for Q1 27, beating the estimate of 54.92 USD, resulting in a 28.43% surprise. Revenue reached 1.22 trillion, compared to an expected 1.16 trillion, with a 5.40% difference. The market reacted with a -2.82% price change (close before vs. close after earnings).
Looking ahead to Q2 27, -- analysts forecast an EPS of 47.57 USD, with revenue projected to reach 1.16 trillion USD, implying an decrease of -32.56% EPS, and decrease of -5.07% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
CDT Equity Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-Actual
-$8.71
Surprise
-
FAQ
What were Takeda Pharmaceutical Company Limited - ADR's earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Takeda Pharmaceutical Company Limited - ADR reported EPS of $70.54, beating estimates by 28.43%, and revenue of $1.22T, 5.4% above expectations.
How did the market react to Takeda Pharmaceutical Company Limited - ADR's Q1 2027 earnings?
The stock price moved down -2.82%, changed from $17.75 before the earnings release to $17.25 the day after.
When is Takeda Pharmaceutical Company Limited - ADR expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Takeda Pharmaceutical Company Limited - ADR's next earnings report?
Based on --
analysts, Takeda Pharmaceutical Company Limited - ADR is expected to report EPS of $47.57 and revenue of $1.16T for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement